Skip to Content

Potential New Standard of Care for Locally Advanced Cervical Cancer

In this MEDtalk from ESMO 2023, Kristina Lindemann briefs us on the Keynote A18 study, where patients with High-risk locally advanced cervical cancer received pembrolizumab in addition to standard chemo-radiation, vs induction chemotherapy prior to chemo-radiation in the same disease setting. These studies offer the potential to improve the standard of care for patients with locally advanced cervical cancer, also in low and middle-income countries where access to newer treatments like immunotherapy and radiation can be challenging.

Kristina Lindemann

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top